Magda Bujar the Manager of Strategic Development at CIRS – a neutral, independently managed UK-based subsidiary company, forming part of Clarivate Analytics (UK) Limited. CIRS’ mission is to maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and HTA policies and processes.
In her current role, she is responsible for developing and executing strategies for engaging with CIRS stakeholders – pharmaceutical companies as well as major regulatory authorities. As part of that also initiates and coordinates special projects with regulatory/HTA agencies and companies as well as other research organisations, from proposal writing, client interactions and project delivery. She has represented CIRS at major scientific meetings, including ICH, DIA and PSWC, as well as authored and co-authored a number of briefings, books and journal articles, focusing on various aspects of regulatory and reimbursement science. Her research interests include the assessment of international regulatory processes, strategies and decision-making practices as well as public policy issues that relate to expediting patient access to medicines.
Prior to joining CIRS, Magda carried our research spanning the scientific, engineering and policy issues regarding the development of medicines. She received her undergraduate degree in Biochemistry from the University of Bristol, a Master of Science in Biochemical Engineering from the University College London and a Doctor in Philosophy from the University of Hertfordshire. Her doctoral work focused on the development of a framework for decision-making during the development, regulatory review and reimbursement of medicines.